Catalyst
Slingshot members are tracking this event:
Novartis (NVS) to submit biosimilar Adalimumab to FDA for arthritis in second half of 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| NVS | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 16, 2018
Occurred Source:
https://www.novartis.com/news/media-releases/sandoz-regulatory-submission-proposed-biosimilar-adalimumab-accepted-fda
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Adalimumab, Biosimilar, Fda Review
